Mirum Pharmaceuticals, Inc. (MIRM)

NGM – Real Time Price. Currency in USD

99.73

+1.50 (1.53%)

Market open: Aug 12, 2026, 11:07 AM EDT

98.23

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Stock details

Previous close: 98.7$
Day's range: 97.41 - 100.57$
52-week range: 63.23 - 130$
Volume: 867 966
Average volume: 893 715
Beta: 0.84
EPS (TTM): -14.54
PE ratio (TTM): N/A
Forward P/E: N/A
Market cap: 6 408 808 749
Shares outstanding: 64 932 206
Dividend yield: N/A
Next earnings date: 2026-11-17
Sector: Healthcare
Industry: Biotechnology

About the company

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States ... read more

CEO: Christopher Peetz
Country: United States
IPO Date: 2019-07-18
Employees: 418
Fiscal Year End: January - December
Website: https://www.mirumpharma.com

Revenue Breakdown

Pharmaceutical / 100.00%

News

No Data

There are no news for this stock.

Chart: MIRM

Loading Chart...

Overall Score

3.5 / 1035%

Octagon View

Strength & Weakness

Total debt $762.9M significantly exceeds cash reserves ($330.7M), raising financial stability concerns

Total current assets $636.3M exceed Total current liabilities $222.8M, highlighting excellent liquidity

Debt-to-equity ratio (-73.2) is well below the industry average (0.3), showcasing prudent financial management

Interest coverage ratio (-10.0x) is dangerously low, suggesting debt repayment risks

Negative free cash flow -$44.3M limits the company's ability to reinvest or pay down debt

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	2.86	6.05	10
Quick ratio	2.74	5.63	10
Debt to Equity	N/A	0.30	1.0
Debt to Assets	0.73	1.04	2.0
Interest coverage	-9.97	-16.91	1.0
Weighted average score			4.8

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	77M	186M	337M	521M	618M
Gross Profit	64M	139M	255M	421M	505M
Operating Income	-131M	-109M	-88M	-22M	-91M
Net Income	-136M	-163M	-88M	-23M	-860M
EBITDA	-128M	-98M	-64M	2M	-65M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	82.65	-11.73	10
Operating margin %	-14.81	-24.60	1.0
Net margin %	-38.14	-172.20	1.0
EBITDA margin %	-10.87	-201.27	1.0
Cash flow margin %	-25.11	-156.39	1.0
Weighted average score			2.8

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	-51.75	-57.97	1.0
ROE	-265.81	-63.56	1.0
ROIC	-71.21	-42.57	1.0
ROCE	-3.42	-71.10	1.0
Weighted average score			1.0

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	33.59	-1154.23	5.5
Next quarter	22.89	-533.64	5.5
Current year	33.63	-3124.48	5.5
Next year	16.66	95.05	9.5
Weighted average score			6.5

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	10.23	91.49	92.11	80.7	9.3
Y/Y	37.92	-1047.01	-783.32	-471.61	3.3
3y average	92.45	33.06	43.21	214.04	10
5y average	315.8	11.26	23.36	120.55	9.3
Weighted average score					8.0

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	N/A	-5.25	1.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	9.14	64.66	6.4
P/B	26.59	2.96	2.2
Weighted average score			2.7

DCF Model

DCF Model Period5 years

Discount rate8.5%

Perpetual growth rate3%

Revenue 5 year CAGR79.93%

FCF 5 year CAGR4

Fair value27.65$

Stock price98.7$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$27.65

UndervaluedStock priceOvervalued

$98.7

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Christopher Peetz

Country

United States

IPO Date

2019-07-18

Employees

418

Fiscal Year End

January - December

Website

https://www.mirumpharma.com

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

2.86

6.05

Quick ratio

2.74

5.63

Debt to Equity

N/A

0.30

1.0

Debt to Assets

0.73

1.04

2.0

Interest coverage

-9.97

-16.91

1.0

Weighted average score

4.8

METRIC

2022

2023

2024

2025

TTM

Total Revenue

77M

186M

337M

521M

618M

Gross Profit

64M

139M

255M

421M

505M

Operating Income

-131M

-109M

-88M

-22M

-91M

Net Income

-136M

-163M

-88M

-23M

-860M

EBITDA

-128M

-98M

-64M

-65M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

82.65

-11.73

Operating margin %

-14.81

-24.60

1.0

Net margin %

-38.14

-172.20

1.0

EBITDA margin %

-10.87

-201.27

1.0

Cash flow margin %

-25.11

-156.39

1.0

Weighted average score

2.8

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

-51.75

-57.97

1.0

ROE

-265.81

-63.56

1.0

ROIC

-71.21

-42.57

1.0

ROCE

-3.42

-71.10

1.0

Weighted average score

1.0

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

33.59

-1154.23

5.5

Next quarter

22.89

-533.64

5.5

Current year

33.63

-3124.48

5.5

Next year

16.66

95.05

9.5

Weighted average score

6.5

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

10.23

91.49

92.11

80.7

9.3

Y/Y

37.92

-1047.01

-783.32

-471.61

3.3

3y average

92.45

33.06

43.21

214.04

5y average

315.8

11.26

23.36

120.55

9.3

Weighted average score

8.0

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

N/A

-5.25

1.0

PEG (5yr expected)

N/A

0.27

1.0

P/S

9.14

64.66

6.4

P/B

26.59

2.96

2.2

Weighted average score

2.7

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Mirum Pharmaceuticals, Inc. (MIRM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Mirum Pharmaceuticals, Inc. (MIRM)

Stock details

About the company

Revenue Breakdown

News

Chart: MIRM

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$27.65

$98.7

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: MIRM

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$27.65

$98.7

Economic Moat